BPI fold containing family A member 4, pseudogeneGenealiases: BASE · LATH
Q-omics provides the consensus-scored BPIFA4P profile across patient tissues and cancer cell-line models. BPIFA4P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BPIFA4P is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, BPIFA4P RNA expression shows 6,698 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, BRCA, and STAD as cancer lineages where BPIFA4P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BPIFA4P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BPIFA4P survival associations across molecular data types. BPIFA4P RNA expression shows survival associations in the most cancer types (19), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BPIFA4P RNA expression–survival associations across cancer types. High BPIFA4P expression shows unfavorable associations in KIRC, UCEC, DLBC and CHOL, but favorable associations in LAML and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BPIFA4P RNA expression.
This table summarizes BPIFA4P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for BPIFA4P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BPIFA4P shows higher tumor expression in BRCA, PRAD, KICH, LUAD and KIRP. The BRCA box plot shows higher BPIFA4P RNA expression in tumor versus normal tissue (log2 FC = +0.129, t-test p < 0.001).
This table shows molecular features associated with BPIFA4P in patient tissues and cancer cell lines. In patient samples, BPIFA4P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
